Respiratory syncytial virus particles (blue) in human lung cells
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH / SCIENCE PHOTO LIBRARY
A vaccine that protects against one of the main common cold viruses has been shown to be safe and effective in a clinical trial and could be available by 2024.
Respiratory syncytial virus (RSV) is so contagious that more than 90 per cent of people have experienced their first infection by the age of 2. It usually causes cold symptoms but can lead to severe illness in young children and older people. Globally, around 60,000 children …
You may also like
-
COVID Vaccine Tracker
-
New Bariatric Portion Plate Helps Bariatric Patients Reach Their Goals
-
2021 preview: how soon will a Covid-19 vaccine normalize life?
-
Official British statisticians had concerns about the trend in the Covid-19 poll
-
NASA’s probe on Mars may feel the ground shake when rovers land in 2021